Athmane Bouroubi

ORCID: 0000-0002-6345-4662
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neurofibromatosis and Schwannoma Cases
  • Vascular Malformations and Hemangiomas
  • Respiratory and Cough-Related Research
  • Dupuytren's Contracture and Treatments
  • Nausea and vomiting management
  • Musculoskeletal pain and rehabilitation
  • Vascular Malformations Diagnosis and Treatment
  • Tumors and Oncological Cases
  • Soft tissue tumor case studies
  • Pediatric health and respiratory diseases
  • Anesthesia and Pain Management
  • Pain Management and Placebo Effect
  • Soft tissue tumors and treatment
  • Fibromyalgia and Chronic Fatigue Syndrome Research
  • Cancer and Skin Lesions
  • melanin and skin pigmentation
  • Hair Growth and Disorders
  • Cancer-related gene regulation
  • dental development and anomalies

Pierre Fabre (France)
2017-2023

Pierre Fabre (Germany)
2011

There is no consensus on optimal treatment duration for propranolol in infantile hemangioma (IH). We evaluated the efficacy and safety of oral solution administered a minimum 6 months up to maximum 12 age high-risk IH.This single-arm, open-label, phase 3 study was conducted patients aged 35 150 days with IH 10 hospitals between 2015 2017. The comprised 6-month initial period (ITP) plus continuation if complete success not achieved, follow-up, retreatment period. Patients received twice daily...

10.1542/peds.2017-3866 article EN PEDIATRICS 2018-08-06

Abstract Background Neurofibromatosis type 1 is an inherited condition with variable phenotypic expression and a high medical social burden. The objectives of this patient survey were to better understand the real-world experiences patients living cutaneous neurofibromas (cNF), perceive their satisfaction feelings about cNF current management (only laser surgery are currently available), highlight expectations new therapeutic modalities. Results One hundred seventy from 4 European countries...

10.1186/s13023-019-1265-4 article EN cc-by Orphanet Journal of Rare Diseases 2019-12-01

X-linked hypohidrotic ectodermal dysplasia (XLHED) is a rare genetic disorder characte-rised by abnormal development of the skin and its appendages, such as hair sweat glands, teeth, mucous glands airways, resulting in serious, sometimes life-threatening complications like hyperthermia or recurrent respiratory infections. It caused pathogenic variants ectodysplasin A gene (EDA). Most affected males are hemizygous for EDA null mutations that lead to absence inactivity signalling protein A1...

10.3390/genes14010153 article EN Genes 2023-01-06

Objective. This double-blind, 1-year extension study investigated the longterm efficacy and safety of milnacipran 100, 150, 200 mg/day in treatment fibromyalgia (FM) completers a 3-month European double-blind lead-in versus placebo. Methods. A total 468 patients with FM successfully completing were either blindly maintained on (MLN200:MLN200, n = 198) or (if previously receiving placebo) rerandomized to 100 (PBO:MLN100, 91), 150 (PBO:MLN150, 92), (PBO:MLN200, 87) for an additional 12 months...

10.3899/jrheum.101025 article EN The Journal of Rheumatology 2011-04-01

Objective The aim of this study was to compare the efficacy and safety a new oromucosal ibuprofen form, 25 mg lozenge, in single repeat dosing for up 4 days, matched placebo, treatment acute sore throat pain adults. Methods In randomised, double-blind, placebo-controlled trial, adult patients with non-streptococcal signs moderate-to-severe associated (≥5 on objective Tonsillo-Pharyngitis Assessment 21-point scale ≥60 mm subjective 0-100 visual analogue Sore Throat Pain Intensity Scale...

10.1111/ijcp.12961 article EN International Journal of Clinical Practice 2017-09-01

Summary Background Androgenetic alopecia ( AGA ) is the most common cause of hair loss in men. Topical minoxidil solutions can help to treat but have be applied continuously effective. Objectives A new formulation with improved cosmetic characteristics DC 0120, Pierre‐Fabre Dermatologie) was tested for noninferiority vs a comparator product ALOSTIL ® , Johnson & Johnson) stimulating growth men . Methods Two 10 cm 2 areas on scalp each subject were randomized receive comparator, or one...

10.1111/jocd.12541 article EN Journal of Cosmetic Dermatology 2018-04-16
Coming Soon ...